AVITA Medical, Inc. (RCEL)
| Market Cap | 484.01M +392.9% |
| Revenue (ttm) | 75.63M +1.0% |
| Net Income | -43.08M |
| EPS | -1.44 |
| Shares Out | 30.93M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 597,051 |
| Open | 16.54 |
| Previous Close | 16.71 |
| Day's Range | 15.24 - 16.60 |
| 52-Week Range | 3.22 - 16.90 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 13.57 (-13.29%) |
| Earnings Date | Nov 5, 2026 |
About RCEL
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi... [Read more]
Financial Performance
In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for RCEL stock is "Strong Buy." The 12-month stock price target is $13.57, which is a decrease of -13.29% from the latest price.
News
AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transfor...
Avita Medical price target raised to $15 from $11 at BTIG
BTIG raised the firm’s price target on Avita Medical (RCEL) to $15 from $11 and keeps a Buy rating on the shares as part of a broader research note previewing…
AVITA Medical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership emphasized operational focus and disciplined execution, driving strong sequential growth and improved financials. The company is deepening penetration in existing accounts, expanding its product portfolio, and targeting cash flow breakeven by Q4 2026, with significant market opportunity ahead.
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced t...
Avita Medical price target raised to $12 from $8 at Lake Street
Lake Street raised the firm’s price target on Avita Medical (RCEL) to $12 from $8 and keeps a Buy rating on the shares following “positive” PermeaDerm 1 trial results. While…
Avita Medical price target raised to $14 from $12 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Avita Medical (RCEL) to $14 from $12 and keeps a Buy rating on the shares. The firm hosted a…
Avita Medical price target raised to $11 from $7 at BTIG
BTIG raised the firm’s price target on Avita Medical (RCEL) to $11 from $7 and keeps a Buy rating on the shares. The firm is adjusting its model after the…
AVITA Medical Transcript: KOL event
PermeaDerm demonstrated a 70% cost reduction and comparable clinical outcomes to allograft, with high surgeon and patient satisfaction. Surgeons reported workflow and supply advantages, no safety concerns, and broad applicability, supporting a shift toward integrated wound care platforms.
AVITA Medical Press release: KOL event
AVITA Medical issued a press release on August 18, 2026, disclosing material business information to investors.
AVITA Medical Slides: KOL event
AVITA Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 18, 2026.
Avita Medical reports PermeaDerm-I clinical study meets primary endpoint
Avita Medical (RCEL) announced results from its multicenter, randomized controlled PermeaDerm-I clinical study demonstrating PermeaDerm, a biosynthetic wound matrix, delivered clinically comparable ou...
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
AVITA Medical's PermeaDerm study shows 70% lower product cost than allograft, with comparable clinical outcomes and a 96% reduction in preparation time.
AVITA Medical Transcript: Investor update
Revenue guidance raised to $86-$89 million for 2026, with cash flow breakeven expected in Q4. Strong sequential revenue growth, stable margins, and disciplined OpEx support this outlook. Nationwide CMS reimbursement changes and international expansion further strengthen growth prospects.
AVITA Medical Slides: Investor update
AVITA Medical has posted slides in relation to its latest quarterly earnings report, which was published on August 12, 2026.
AVITA Medical Transcript: Canaccord Genuity's 46th Annual Growth Conference
Sequential revenue growth, raised guidance, and cost discipline position the business for cash flow breakeven by year-end. The three-product portfolio is gaining adoption, supported by strong clinical and economic data, with further growth expected as reimbursement simplifies in 2027.
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholde...
Avita Medical price target raised to $8 from $6 at Lake Street
Lake Street analyst Frank Takkinen raised the firm’s price target on Avita Medical (RCEL) to $8 from $6 and keeps a Buy rating on the shares after what the firm…
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it...
Avita Medical upgraded to Buy from Neutral at BTIG
BTIG upgraded Avita Medical (RCEL) to Buy from Neutral with a $7 price target The firm, which believes that Q2 results reflect a business executing better than it did through…
Avita Medical reports Q2 EPS (25c), consensus (39c)
Reports Q2 revenue $21.7M, consensus $28.7M. The company said, “We delivered a strong second quarter, with revenue growing 18% year-over-year and 13% sequentially. As AVITA continues to expand utiliza...
AVITA Medical Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 18% year-over-year to $21.7 million, driven by strong adoption of RECELL and supporting products. Gross margin remained high at 81.9%, and guidance was raised to $86–$89 million for 2026, with cash flow breakeven expected in Q4.
AVITA Medical Earnings release: Q2 2026
AVITA Medical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
AVITA Medical Quarterly report: Q2 2026
AVITA Medical has published its Q2 2026 quarterly earnings report on August 6, 2026.
AVITA Medical Slides: Q2 2026
AVITA Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” ...